US › Healthcare

PepGen Ltd (PEPG)

US · Healthcare · Biotechnology

$2.60+2.77%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-17.8M

EPS

$-0.26

EPS estimate

$-0.30

EPS came in at -0.26 against a street estimate of -0.30 — a beat of 13.3%.

Key statistics

Market cap

$163.2M

Forward P/E

0.0

P/B

1.73

Book value

$1.73

EPS (TTM)

$-0.94

52-week high

$7.80

52-week low

$1.31

50-day MA

$2.81

200-day MA

$3.26

Beta

2.01

Analyst view

Analysts rate PepGen Ltd a strong buy (7 buy, 0 hold, 1 sell out of 8) with an average price target of $10.19.

Shareholding

Insiders

0.23%

Institutions

82.86%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	28.97%
COMMODORE CAPITAL LP	6.46%
Viking Global Investors LP	5.03%
LAURION CAPITAL MANAGEMENT LP	3.97%
ADAR1 Capital Management LLC	3.74%
Vivo Capital, LLC	3.36%
Vanguard Capital Management, LLC	2.80%
Millennium Management LLC	2.58%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for PepGen Ltd — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.